Method of treating hypertension

Patent metadata

Field	Value
Publication number	US-11478483-B2
Application number	US-201816123553-A
Country	US
Kind code	B2
Filing date	Sep 6, 2018
Priority date	Sep 8, 2017
Publication date	Oct 25, 2022
Grant date	Oct 25, 2022

Abstract

Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of Quetiapine or derivative thereof. The compositions include an effective amount of Quetiapine or derivative thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension.

First claim

The invention claimed is:

1. A method of treating pulmonary hypertension in a patient in need thereof, comprising administering to the patient a composition comprising an effective amount of a quetiapine or a pharmaceutically acceptable salt or ester thereof,
wherein the pulmonary hypertension is pulmonary arterial hypertension.

2. The method of claim 1 , wherein the patient has a resting pulmonary arterial pressure greater than 14 mm Hg.

3. The method of claim 1 , wherein the patient has a resting pulmonary arterial pressure
greater than 40 mm Hg.

4. The method of claim 1 , wherein quetiapine is administered in an amount effective to lower resting pulmonary arterial blood pressure to a level no greater than 18 mm Hg.

5. The method of claim 1 , wherein quetiapine is administered in an amount effective to lower resting pulmonary arterial blood pressure at least 5% relative to the resting
pulmonary arterial blood pressure prior to commencing treatment.

6. The method of claim 1 , wherein quetiapine is administered in a dose from 0.1 to 50 mg.

7. The method of claim 1 , wherein the composition comprises quetiapine fumarate.

8. The method of claim 7 , wherein the composition is administered orally, by injection, parenterally, buccally, transdermally, or by inhalation.

9. The method of claim 7 , wherein the composition is administered orally.

10. The method of claim 7 , wherein the composition is administered parenterally.

11. The method of claim 1 , further comprising administering at least one additional agent effective to treat pulmonary hypertension.

12. The method of claim 11 , wherein the at least one additional agent comprises one or more of phosphodiesterase inhibitors, calcium channel blockers, endothelin receptor antagonists, inotropic agents, prostacyclin pathway agonists, anti-coagulants, guanylate cyclase stimulators, or a combination thereof.

13. The method of claim 11 , wherein the at least one additional agent comprises one or more of avanafil, lodenafil, mirodenafil, sildenafil, tadalafil, vardenafil, udenafil, zaprinast, icariin, amlodipine, nifefipine, diltiazem, bosentan, ambrisentan, sitaxsentan, macitentan, riociguat, toprimate, fusadil, warfarin, digoxin, epoprostenol, treprostinil sodium, iloprost, selexipag, or a combination thereof.

Assignees

• Cipla Ltd

Inventors

• Malhotra Geena
• Joshi Kalpana
• Ghosalkar Jeevan

Classifications

• A61K31/554 Primary

  having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K9/2054

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title